Bioelectronic Cell-based Device Provides a Strategy for the Treatment of the Experimental Model of Multiple Sclerosis

Overview

Journal J Control Release

Specialty Pharmacology

Date 2022 Nov 12

PMID 36370877

Authors

Emilie Audouard

Fanny Michel

Vanessa Pierroz

Taeuk Kim

Lisa Rousselot

Beatrix Gillet-Legrand

Gaelle Dufayet-Chauffaut

Peter Buchmann

Michael Florea

Alexander Khel

Kamilya Altynbekova

Claudia Delgaldo

Encarna Escudero

Alejandra Ben Aissa Soler

Nathalie Cartier

Francoise Piguet

Marc Folcher

Affiliations

Soon will be listed here.

Abstract

Wireless powered optogenetic cell-based implant provides a strategy to deliver subcutaneously therapeutic proteins. Immortalize Human Mesenchymal Stem Cells (hMSC-TERT) expressing the bacteriophytochrome diguanylate cyclase (DGCL) were validated for optogenetic controlled interferon-β delivery (Optoferon cells) in a bioelectronic cell-based implant. Optoferon cells transcriptomic profiling was used to elaborate an in-silico model of the recombinant interferon-β production. Wireless optoelectronic device integration was developed using additive manufacturing and injection molding. Implant cell-based optoelectronic interface manufacturing was established to integrate industrial flexible compact low-resistance screen-printed Near Field Communication (NFC) coil antenna. Optogenetic cell-based implant biocompatibility, and device performances were evaluated in the Experimental Autoimmune Encephalomyelitis (EAE) mouse model of multiple sclerosis.

Citing Articles

The alkaline treatment and its influence on the physicomechanical properties of plantain pseudostem fibers - A comparative study of treated and untreated fibers.

Hurtado-Figueroa O, Varum H, Prieto M, Gallardo Amaya R, Escamilla A Heliyon. 2025; 11(2):e41843.

PMID: 39897780 PMC: 11783020. DOI: 10.1016/j.heliyon.2025.e41843.

Optogenetics in oral and craniofacial research.

Zhang Q, Song L, Fu M, He J, Yang G, Jiang Z J Zhejiang Univ Sci B. 2024; 25(8):656-671.

PMID: 39155779 PMC: 11337086. DOI: 10.1631/jzus.B2300322.

Practical Use of Immortalized Cells in Medicine: Current Advances and Future Perspectives.

Voloshin N, Tyurin-Kuzmin P, Karagyaur M, Akopyan Z, Kulebyakin K Int J Mol Sci. 2023; 24(16).

PMID: 37628897 PMC: 10454025. DOI: 10.3390/ijms241612716.

References

Folcher M, Oesterle S, Zwicky K, Thekkottil T, Heymoz J, Hohmann M . Mind-controlled transgene expression by a wireless-powered optogenetic designer cell implant. Nat Commun. 2014; 5:5392. PMC: 4241983. DOI: 10.1038/ncomms6392. View

Valadkhan S, Plasek L . Long Non-Coding RNA-Mediated Regulation of the Interferon Response: A New Perspective on a Familiar Theme. Pathog Immun. 2018; 3(1):126-148. PMC: 6101671. View

Sabek O, Farina M, Fraga D, Afshar S, Ballerini A, Filgueira C . Three-dimensional printed polymeric system to encapsulate human mesenchymal stem cells differentiated into islet-like insulin-producing aggregates for diabetes treatment. J Tissue Eng. 2016; 7:2041731416638198. PMC: 4843232. DOI: 10.1177/2041731416638198. View

Simonsen J, Rosada C, Serakinci N, Justesen J, Stenderup K, Rattan S . Telomerase expression extends the proliferative life-span and maintains the osteogenic potential of human bone marrow stromal cells. Nat Biotechnol. 2002; 20(6):592-6. DOI: 10.1038/nbt0602-592. View

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

Tao W . Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther. 2006; 6(7):717-26. DOI: 10.1517/14712598.6.7.717. View

Escalante C, Nistal-Villan E, Shen L, Garcia-Sastre A, Aggarwal A . Structure of IRF-3 bound to the PRDIII-I regulatory element of the human interferon-beta enhancer. Mol Cell. 2007; 26(5):703-16. DOI: 10.1016/j.molcel.2007.04.022. View

Fallegger F, Schiavone G, Lacour S . Conformable Hybrid Systems for Implantable Bioelectronic Interfaces. Adv Mater. 2019; 32(15):e1903904. DOI: 10.1002/adma.201903904. View

He J, Hsuchou H, He Y, Kastin A, Mishra P, Fang J . Leukocyte infiltration across the blood-spinal cord barrier is modulated by sleep fragmentation in mice with experimental autoimmune encephalomyelitis. Fluids Barriers CNS. 2015; 11(1):27. PMC: 4298076. DOI: 10.1186/2045-8118-11-27. View

10.

Visser L, Folcher M, Delgado Simao C, Gutierrez Arechederra B, Escudero E, Uyl-de Groot C . The Potential Cost-Effectiveness of a Cell-Based Bioelectronic Implantable Device Delivering Interferon-β1a Therapy Versus Injectable Interferon-β1a Treatment in Relapsing-Remitting Multiple Sclerosis. Pharmacoeconomics. 2021; 40(1):91-108. PMC: 8739553. DOI: 10.1007/s40273-021-01081-y. View

11.

Luo Y, Wang M, Wan C, Cai P, Loh X, Chen X . Devising Materials Manufacturing Toward Lab-to-Fab Translation of Flexible Electronics. Adv Mater. 2020; 32(37):e2001903. DOI: 10.1002/adma.202001903. View

12.

Lathuiliere A, Laversenne V, Astolfo A, Kopetzki E, Jacobsen H, Stampanoni M . A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies. Brain. 2016; 139(Pt 5):1587-604. DOI: 10.1093/brain/aww036. View

13.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

14.

Waleev T, Shtokalo D, Konovalova T, Voss N, Cheremushkin E, Stegmaier P . Composite Module Analyst: identification of transcription factor binding site combinations using genetic algorithm. Nucleic Acids Res. 2006; 34(Web Server issue):W541-5. PMC: 1538785. DOI: 10.1093/nar/gkl342. View

15.

Boyarskikh U, Pintus S, Mandrik N, Stelmashenko D, Kiselev I, Evshin I . Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3. BMC Med Genomics. 2018; 11(Suppl 1):12. PMC: 5836833. DOI: 10.1186/s12920-018-0330-5. View

16.

Schwenter F, Zarei S, Luy P, Padrun V, Bouche N, Lee J . Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy. Cancer Gene Ther. 2011; 18(8):553-62. DOI: 10.1038/cgt.2011.22. View

17.

Goldschmidt C, Hua L . Re-Evaluating the Use of IFN-β and Relapsing Multiple Sclerosis: Safety, Efficacy and Place in Therapy. Degener Neurol Neuromuscul Dis. 2020; 10:29-38. PMC: 7326221. DOI: 10.2147/DNND.S224912. View

18.

Twine N, Harkness L, Adjaye J, Aldahmash A, Wilkins M, Kassem M . Molecular Phenotyping of Telomerized Human Bone Marrow Skeletal Stem Cells Reveals a Genetic Program of Enhanced Proliferation and Maintenance of Differentiation Responses. JBMR Plus. 2018; 2(5):257-267. PMC: 6139702. DOI: 10.1002/jbm4.10050. View

19.

Salmi M . Additive Manufacturing Processes in Medical Applications. Materials (Basel). 2021; 14(1). PMC: 7796413. DOI: 10.3390/ma14010191. View

20.

Petry H, Cashion L, Szymanski P, Ast O, Orme A, Gross C . Mx1 and IP-10: biomarkers to measure IFN-beta activity in mice following gene-based delivery. J Interferon Cytokine Res. 2006; 26(10):699-705. DOI: 10.1089/jir.2006.26.699. View